Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study
Janni W, Friedl T, Zwingers T, Huober J, Scholz C, Annecke K, Wischnik A, Jueckstock J, Augustin D, Rack B, Harbeck N, Kiechle M. Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study. Br J Cancer 2016; 114:863-71.
Mar 31, 2016Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study
Mar 31, 2016Br J Cancer 2016; 114:863-71
Janni W, Friedl T W P, Zwingers T, Huober Jens, Scholz C, Annecke K, Wischnik A, Jueckstock J, Augustin D, Rack B, Harbeck N, Kiechle M
Development of new Malt1 inhibitors and probes
Xin B, Schimmack G, Du Y, Florea B, van der Marel G, Driessen C, Krappmann D, Overkleeft H. Development of new Malt1 inhibitors and probes. Bioorg Med Chem 2016; 24:3312-29.
Mar 28, 2016Development of new Malt1 inhibitors and probes
Mar 28, 2016Bioorg Med Chem 2016; 24:3312-29
Xin Bo-Tao, Schimmack Gisela, Du Yimeng, Florea Bogdan I, van der Marel Gijsbert A, Driessen Christoph, Krappmann Daniel, Overkleeft Herman S
Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08
Hitz F, Rondeau S, Berardi Vilei S, Eckhardt K, Enoiu M, Rothermundt C, Schmidt A, Krasniqi F, Mach N, Caspar C, Samaras P, Cairoli A, Fischer N, Pabst T, Zucca E, Mey U. Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08. Br J Haematol 2016
Mar 28, 2016Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08
Mar 28, 2016Br J Haematol 2016
Hitz Felicitas, Rondeau Stephanie, Berardi Vilei Simona, Eckhardt Katrin, Enoiu Milica, Rothermundt Christian, Schmidt Adrian, Krasniqi Fatime, Mach Nicolas, Caspar Clemens B, Samaras Panagiotis, Cairoli Anne, Fischer Natalie, Pabst Thomas, Zucca Emanuele, Mey Ulrich
Management der akuten Meningitis und Enzephalitis
Leupold D, Boggian K, Weber J, Tettenborn B, Hundsberger T. Management der akuten Meningitis und Enzephalitis - Ein klinischer Leitfaden. Praxis (Bern 1994) 2016; 105:1471-1478.
Mar 26, 2016Management der akuten Meningitis und Enzephalitis
Mar 26, 2016Praxis (Bern 1994) 2016; 105:1471-1478
Leupold Daniela, Boggian Katia, Weber Johannes, Tettenborn Barbara, Hundsberger Thomas
Karfreitag heute
Renz M. Karfreitag heute. Tiroler Tageszeitung 2016; Sonderbeilage mit Thema Ostern
Mar 25, 2016Karfreitag heute
Mar 25, 2016Tiroler Tageszeitung 2016; Sonderbeilage mit Thema Ostern
Renz Monika
The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity
Hamzic S, Wenger N, Froehlich T, Jörger M, Aebi S, Largiader C, Amstutz U. The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity. Pharmacogenomics J 2016
Mar 22, 2016The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity
Mar 22, 2016Pharmacogenomics J 2016
Hamzic S, Wenger N, Froehlich T K, Jörger Markus, Aebi S, Largiader C R, Amstutz U
Predictive value of mucinous histology in colon cancer: a population-based, propensity score matched analysis
Warschkow R, Tarantino I, Hüttner F, Schmied B, Gueller U, Diener M, Ulrich A. Predictive value of mucinous histology in colon cancer: a population-based, propensity score matched analysis. Br J Cancer 2016; 114:1027-32.
Mar 15, 2016Predictive value of mucinous histology in colon cancer: a population-based, propensity score matched analysis
Mar 15, 2016Br J Cancer 2016; 114:1027-32
Warschkow Rene, Tarantino Ignazio, Hüttner Felix J, Schmied Bruno, Gueller Ulrich, Diener Markus K, Ulrich Alexis
Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
Baselga J, de Haas S, Olsen S, Samant M, Guardino A, Huober J, Ro J, Verma S, Lewis Phillips G, Pegram M. Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer. Clin Cancer Res 2016; 22:3755-63.
Feb 26, 2016Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
Feb 26, 2016Clin Cancer Res 2016; 22:3755-63
Baselga José, de Haas Sanne L, Olsen Steve, Samant Meghna K, Guardino Alice E, Huober Jens, Ro Jungsil, Verma Sunil, Lewis Phillips Gail D, Pegram Mark D
Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab
Bossi P, Canevari S, Licitra L, Locati L, Pilotti S, Perrone F, Cortelazzi B, Marchesi E, Giannoccaro M, Favales F, Sponghini A, Cossu Rocca M, Siano M, Bergamini C, De Cecco L. Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab. Clin Cancer Res 2016; 22:3961-70.
Feb 26, 2016Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab
Feb 26, 2016Clin Cancer Res 2016; 22:3961-70
Bossi Paolo, Canevari Silvana, Licitra Lisa, Locati Laura D, Pilotti Silvana, Perrone Federica, Cortelazzi Barbara, Marchesi Edoardo, Giannoccaro Marco, Favales Federica, Sponghini Andrea P, Cossu Rocca Maria, Siano Marco, Bergamini Cristiana, De Cecco Loris
The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma
Dummer R, Guckenberger M, Najafi Y, von Moos R, Mihic-Probst D, Michielin O, Braun R, Lindenblatt N, Hunger R, Siano M, Arnold A. The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma. Swiss Med Wkly 2016; 146:w14279.
Feb 22, 2016The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma
Feb 22, 2016Swiss Med Wkly 2016; 146:w14279
Dummer Reinhard, Guckenberger Merlin, Najafi Yousef, von Moos Roger, Mihic-Probst Daniela, Michielin Oliver, Braun Ralph, Lindenblatt Nicole, Hunger Robert E, Siano Marco, Arnold Andreas
Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial
Gluz O, Augustin D, Hoffmann G, Thomssen C, Jänicke F, Kiechle M, Wallwiener D, Kuhn W, Nitz U, Möbus V, Mohrmann S, Liedtke C, Huober J, Peyro-Saint-Paul H, Kates R, Kreipe H, Hartmann A, Pelz E, Erber R, Harbeck N. Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial. Ann Oncol 2016; 27:1035-1040.
Feb 18, 2016Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial
Feb 18, 2016Ann Oncol 2016; 27:1035-1040
Gluz O, Augustin D, Hoffmann G, Thomssen C, Jänicke F, Kiechle M, Wallwiener D, Kuhn W, Nitz U, Möbus V, Mohrmann S, Liedtke C, Huober Jens, Peyro-Saint-Paul H, Kates R E, Kreipe H H, Hartmann A, Pelz E, Erber R, Harbeck N
Isolated tumor cells in stage I & II colon cancer patients are associated with significantly worse disease-free and overall survival
Weixler B, Warschkow R, Gueller U, Zettl A, von Holzen U, Schmied B, Zuber M. Isolated tumor cells in stage I & II colon cancer patients are associated with significantly worse disease-free and overall survival. BMC cancer 2016; 16:106.
Feb 16, 2016Isolated tumor cells in stage I & II colon cancer patients are associated with significantly worse disease-free and overall survival
Feb 16, 2016BMC cancer 2016; 16:106
Weixler B, Warschkow Rene, Gueller Ulrich, Zettl A, von Holzen U, Schmied B M, Zuber M
Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer?
Bekes I, Friedl T, Köhler T, Möbus V, Janni W, Wöckel A, Wulff C. Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer?. Mol Cancer 2016; 15:13.
Feb 12, 2016Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer?
Feb 12, 2016Mol Cancer 2016; 15:13
Bekes Inga, Friedl Thomas W P, Köhler Tanja, Möbus Volker, Janni Wolfgang, Wöckel Achim, Wulff Christine
Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials
Böll B, Engert A, Diehl V, Fuchs M, Borchmann S, Bürkle C, Eichenauer D, von Tresckow B, Greil R, Kerkhoff A, Hitz F, Bröckelmann P, Behringer K, Goergen H, Borchmann P. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood 2016; 127:2189-92.
Feb 1, 2016Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials
Feb 1, 2016Blood 2016; 127:2189-92
Böll Boris, Engert Andreas, Diehl Volker, Fuchs Michael, Borchmann Sven, Bürkle Carolin, Eichenauer Dennis A, von Tresckow Bastian, Greil Richard, Kerkhoff Andrea, Hitz Felicitas, Bröckelmann Paul J, Behringer Karolin, Goergen Helen, Borchmann Peter
[Metformin for the treatment of polycystic ovary syndrome]
Gundelach T, Rodewald M, Bekes I, Janni W, Hancke K. [Metformin for the treatment of polycystic ovary syndrome]. Med Monatsschr Pharm 2016; 39:75-8.
Feb 1, 2016[Metformin for the treatment of polycystic ovary syndrome]
Feb 1, 2016Med Monatsschr Pharm 2016; 39:75-8
Gundelach Theresa, Rodewald Miriam, Bekes Inga, Janni Wolfgang, Hancke Katharina
Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer
Pérez-López R, Koh D, de Bono J, Leach M, Zivi A, Omlin A, Bianchini D, Mateo J, Collins D, Blackledge M, Lorente D, Tunariu N. Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer. Radiology 2016; 280:151-60.
Jan 25, 2016Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer
Jan 25, 2016Radiology 2016; 280:151-60
Pérez-López Raquel, Koh Dow-Mu, de Bono Johann S, Leach Martin O, Zivi Andrea, Omlin Aurelius, Bianchini Diletta, Mateo Joaquin, Collins David J, Blackledge Matthew D, Lorente David, Tunariu Nina
Reply to the letter to the editor 'Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy' by Tannock et al
Parker C, Gillessen Sommer S, Heidenreich A, Horwich A. Reply to the letter to the editor 'Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy' by Tannock et al. Ann Oncol 2016; 27:750-1.
Jan 22, 2016Reply to the letter to the editor 'Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy' by Tannock et al
Jan 22, 2016Ann Oncol 2016; 27:750-1
Parker C, Gillessen Sommer Silke, Heidenreich A, Horwich A
Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V
Colleoni M, Coates A, Gelber R, Castiglione M, Gianni L, Thürlimann B, Forbes J, Karlsson P, Price K, Sun Z, Goldhirsch A. Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. J Clin Oncol 2016
Jan 19, 2016Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V
Jan 19, 2016J Clin Oncol 2016
Colleoni Marco, Coates Alan S, Gelber Richard D, Castiglione Monica, Gianni Lorenzo, Thürlimann Beat, Forbes John F, Karlsson Per, Price Karen N, Sun Zhuoxin, Goldhirsch Aron
Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns
Kampa-Schittenhelm K, Salitzky O, Akmut F, Illing B, Kanz L, Salih H, Schittenhelm M. Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns. BMC cancer 2016; 16:25.
Jan 16, 2016Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns
Jan 16, 2016BMC cancer 2016; 16:25
Kampa-Schittenhelm Kerstin, Salitzky Olaf, Akmut Figen, Illing Barbara, Kanz Lothar, Salih Helmut Rainer, Schittenhelm Marcus
Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer
Loibl S, Untch M, von Minckwitz G, Mehta K, Jackisch C, Tiemann K, Fasching P, Pfitzner B, Eidtmann H, Hartmann A, Lederer B, Furlanetto J, Klimowicz A, Huober J, Darb-Esfahani S, Denkert C. Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer. Clin Cancer Res 2016; 22:2675-83.
Jan 12, 2016Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer
Jan 12, 2016Clin Cancer Res 2016; 22:2675-83
Loibl Sibylle, Untch Michael, von Minckwitz Gunter, Mehta Keyur, Jackisch Christian, Tiemann Katharina, Fasching Peter A, Pfitzner Berit, Eidtmann Holger, Hartmann Arndt, Lederer Bianca, Furlanetto Jenny, Klimowicz Alexander, Huober Jens, Darb-Esfahani Silvia, Denkert Carsten